Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
10/09/2026 13:11
BRIEF-Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology Sept 10 (Reuters) - Adagene Inc. 978y.F:
ADAGENE ANNOUNCES THAT THIRD ARC BIO HAS SELECTED FIRST LEAD CANDIDATE UNDER AMENDED STRATEGIC COLLABORATION FOR DEVELOPMENT OF MASKED CD3 T CELL ENGAGERS UTILIZING SAFEBODY® TECHNOLOGY
ADAGENE - TOTAL POTENTIAL PAYMENTS TO ADAGENE UNDER COLLABORATION INCREASED
Source text: ID:nGNX5xPv6D
Further company coverage: [978y.F]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate